This study focuses on dementia and mild cognitive impairment (MCI) in older adults. Dementia is a progressive neurodegenerative disorder characterized by cognitive decline, memory impairment, and changes in behavior, affecting daily living activities. MCI is considered an intermediate stage between normal cognitive aging and dementia, where patients exhibit noticeable cognitive decline but do not yet meet the criteria for dementia. The study specifically examines the effects of cholinesterase
Conditions
Interventions
This group consists of patients diagnosed with dementia or mild cognitive impairment (MCI) who have been prescribed cholinesterase inhibitors (ChEIs), including donepezil, galantamine, or rivastigmine
Diagnostic,Diagnostic
Cholinesterase Inhibitor (ChEI) Group,Non Cholinesterase Inhibitor (Non ChEI) Group
Sponsors
Faculty of Medicine, Ramathibodi Hospital, Mahidol University
Eligibility
Sex/Gender
All
Age
60 Years to No maximum
Inclusion criteria
Inclusion criteria: The inclusion criteria are: (i) age 60 and older. (ii) diagnosed with either dementia or mild cognitive impairment. (iii) had HR records during outpatient appointments scheduled at 3, 6, or 12-month intervals, with a two-week window around those dates.
Exclusion criteria
Exclusion criteria: . The exclusion criteria are: (i) HR records are less than three records during the six months before the reference date. (iii) patients with preexisting bradycardia, defined as a baseline heart rate (BHR), calculated by mean value of HR record during 6-month-period before reference, less than 60 beats per minute (bpm), and (iv) those with BHR exceeding 120 bpm.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Heart rate Change 12 months after index dates Heart rate | — |
Secondary
| Measure | Time frame |
|---|---|
| Bradycardia Incidences 12 months after index dates Event | — |
Countries
Thailand
Contacts
Public ContactSmuch Siramongkholkarn
Faculty of Medicine, Ramathibodi hospital
Outcome results
None listed